Publication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathy

Complete healing occurred after 4 weeks in 6 of 10 RGN-259-treated subjects and 1 of 8 placebo-treated subjects, indicating a strong efficacy trend.